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Abstract
Background: Introduction of new antibiotic resistance genes in the plasmids of interest is a
frequent task in molecular cloning practice. Classical approaches involving digestion with restriction
endonucleases and ligation are time-consuming.
Findings: We have created a set of insertion vectors (pINS) carrying genes that provide resistance
to various antibiotics (puromycin, blasticidin and G418) and containing a loxP site. Each vector
(pINS-Puro, pINS-Blast or pINS-Neo) contains either a chloramphenicol or a kanamycin resistance
gene and is unable to replicate in most E. coli strains as it contains a conditional R6Kγ replication
origin. Introduction of the antibiotic resistance genes into the vector of interest is achieved by Cre-
mediated recombination between the replication-incompetent pINS and a replication-competent
target vector. The recombination mix is then transformed into E. coli and selected by the resistance
marker (kanamycin or chloramphenicol) present in pINS, which allows to recover the recombinant
plasmids with 100% efficiency.
Conclusion: Here we propose a simple strategy that allows to introduce various antibiotic-
resistance genes into any plasmid containing a replication origin, an ampicillin resistance gene and
a loxP site.
Background
Antibiotics blasticidin S, puromycin and G418 are fre-
quently used for selection of stably transfected mamma-
lian cell lines [1]. For this purpose plasmid expressing a
gene of interest may be cotransfected with a plasmid con-
taining a convenient antibiotic resistance gene [2,3]. Alter-
natively the antibiotic resistance gene and the gene of
interest can be combined in one plasmid [4].
Unfortunately, the choice of several antibiotic resistance
markers is available only for few types of expression vec-
tors (for example, pcDNA3.1 vector series, Invitrogen) [5].
That is why usually researchers have to introduce new
antibiotic resistance genes into the original vector. In this
case, the cloning strategy may be complicated by the
absence of the unique and convenient restriction sites in
the plasmids containing long inserts.
Here we propose to introduce the antibiotic resistance
genes using recombination (Fig. 1). We have created sev-
eral insertion vectors (pINS-Puro, pINS-Neo, pINS-Blast)
containing the pac  (puromycin-N-acetyl transferase)
[6,7],  aph  (aminoglycoside phosphotransferase) [8,9]
and bsd (blasticidin S deaminase) [10] genes that provide
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resistance to puromycin, G418 (G418 is an aminoglyco-
side, similar in structure to neomycin) and blasticidin S
respectively (Fig 2). pINS vectors can be introduced via
Cre-recombination [11] into several commercially availa-
ble target vectors containing the LoxP sites, for example
phrGFP vector (Stratagene). In addition we created several
new target vectors: pT-FLAG, pT-BS and pT-TK (Fig. 2).
Construction of the insertion vectors pINS
We have used the backbone of the pUNI-10 plasmid
[12,13] (Fig 1, 2) for construction of the insertion vectors
pINS-Puro, pINS-Neo and pINS-Blast. pUNI-10 contains
the R6Kγ origin of replication [14,15] and the LoxP site
[11] recognized by Cre recombinase [16]. R6Kγ origin is
active only in E. coli strains expressing the π-protein
encoded by the pir gene. Cloning and production of the
pINS plasmids was performed in the pir+ E. coli strain
BW23474 expressing the mutant form of the π-protein
(pir-116) that allows to maintain a plasmid with the R6Kγ
origin at a high copy number [17,13].
Thus the pINS vectors contain four principal elements:
-R6Kγ origin of replication;
-LoxP site required for Cre-mediated recombination with
target vector;
-Genes coding for either chloramphenicol acetyl trans-
ferase [18] or aminophosphotransferase [19] providing
the resistance to the antibiotics chloramphenicol (Cam)
or kanamycin (Kan), respectively. These genes are
required for the selection of the recombinant constructs in
E. coli;
General outline of the antibiotic genes introduction via recombination Figure 1
General outline of the antibiotic genes introduction via recombination. pINS plasmids (pINS-Blast, pINS-Puro and 
pINS-Neo) produced in the pir+ E. coli strains can be integrated via Cre-mediated recombination into any of the target vectors 
(phrGFP, pT-FLAG, pT-TK and pT-BS) produced in the pir- E. coli strains. The recombination mix is transformed into the pir- E. 
coli strain and the recombinant plasmid is selected by Kan or Cam markers provided by pINS vector.
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Maps of Target (phRGFP, pT-FLAG, pT-TK and pT-BS) and Insertion (pINS-Blast, pINS-Puro and pINS-Neo) vectors Figure 2
Maps of Target (phRGFP, pT-FLAG, pT-TK and pT-BS) and Insertion (pINS-Blast, pINS-Puro and pINS-Neo) 
vectors. pUNI-10 vector used as a backbone for cloning of the antibiotic resistance genes (Blast, Puro and Neo) is also shown. 
Only relevant restriction sites are shown. Detailed maps are available upon request.BMC Research Notes 2008, 1:135 http://www.biomedcentral.com/1756-0500/1/135
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- Genes coding for either pac (puromycin-N-acetyl trans-
ferase), aph (aminoglycoside phosphotransferase) or bsd
(blasticidin S deaminase) controlled by the SV40 pro-
moter. These genes provide mammalian cells with the
resistance to puromycin, G418, or blasticidin S.
Conventional E. coli strains (XL-1 Blue, DH5α, JM-109
etc.) are pir- and cannot maintain the pINS plasmid. In
contrast, the products of in vitro recombination between
the pINS plasmid and the target vector can successfully
replicate in the pir- strains due to the presence of the active
origin of replication provided by the target vector. The
selection of the recombinant plasmids is achieved by the
markers Kan or Cam provided by pINS plasmid. This
selection procedure allows to achieve 100% yield of
recombinant plasmids (Fig. 1).
Construction of the target vectors
Target vectors compatible with our pINS plasmids must
contain only three necessary elements (Fig. 1):
- the LoxP site;
- An origin of replication active in the pir- E. coli strain, for
example, pUC-origin [20];
- An appropriate antibiotic resistance gene, for example
beta-lactamase (bla) [21] providing resistance to ampicil-
lin (Amp).
We have modified several commercially available plas-
mids (phRL-TK (Promega) and pBluescriptII (Stratagene)
by introduction of the LoxP sites resulting in the target
vectors pT-TK and pT-BS respectively (Fig 2).
pT-TK vector contains the Renilla luciferase gene under
control of the herpes simplex virus thymidine kinase pro-
moter (TK) [22]. pT-TK vector can be used for the expres-
sion of a gene of interest at the levels that are 10-20 times
lower than produced by the CMV promoter at least in
some types of mammalian cells (HeLa, NIH 3T3 [23] and
MEF [23]). For this purpose, the luciferase gene has to be
cut out by NheI and XbaI and replaced by the gene of
interest. Alternatively, any other vector can be used as a
target vector in our system if upgraded by insertion of the
LoxP sites as described [12].
pT-BS vector contains the convenient pBluescriptII
polylinker [24] suitable for cloning of the expression
modules containing a gene of interest under the control of
appropriate promoter.
We have also used the commercially available target vec-
tor phrGFP (Stratagene) already containing the LoxP site.
We have also created a pT-FLAG vector by replacing the
GFP via FLAG-tag in the phrGFP vector (Fig 2).
pT-FLAG vector is coding for the FLAG-tag (DYKDDDDK)
[25] and the cytomegalovirus promoter (CMV) [26]. It is
suitable for cloning and expression of proteins with the N-
terminal FLAG-tag.
All target vectors were cloned and produced in the XL-1
Blue strain (pir-).
Introduction of an antibiotic resistance gene in the target 
vectors by in vitro recombination
We have performed in vitro recombination between the
pINS and the target vectors using Cre-recombinase. We
have transformed the pir- and pir+ E. coli strains (XL-1 Blue
and BW23474 respectively) with the reaction mixture in
order to test the efficiency of the reaction and selected the
transformants using either kanamycin, chloramphenicol
or ampicillin.
Recombination mix contains the product of recombina-
tion (pINS × target vector) as well as the initial pINS and
target vectors that did not take part in the reaction (Fig. 3).
Recombination mix produced ampicillin-resistant colo-
nies in cases of pir- and pir+ strains due to the presence of
the initial target vector (Amp). The pir+ strain transformed
by the recombination mix also produced kanamycin or
chloramphenicol-resistant colonies due to the presence of
the initial pINS vector (Can or Kan). In contrast, we have
observed much fewer kanamycin- or chloramphenicol-
resistant colonies in the pir-  strain transformed by the
recombination mix. These colonies only appear if the cells
receive replication-competent product of recombination
containing the kanamycin/chloramphenicol resistance
gene (pINS × target vector). Alternatively, these colonies
could appear from the contaminants of the initial plas-
mids.
In order to test the purity of our plasmid preparations, we
have also transformed the pINS vectors and the target vec-
tors into both pir- and pir+ strains and selected the trans-
formants using either kanamycin/chloramphenicol or
ampicillin (Fig. 3 and data not shown). As expected, the
pINS vectors did not transform the pir- strain. In contrast,
the pir+ strain transformed by the pINS vector can grow on
either kanamycin or chloramphenicol, but not on ampi-
cillin. The target vector transformed both XL1-Blue (pir-)
and BW23474 (pir+) strains since the activity of the pUC
origin of replication did not depend on the presence of
the pir gene and produced the ampicillin-resistant, but
neither kanamycin- nor chloramphenicol-resistant colo-
nies. This confirmed the purity of the initial plasmids.BMC Research Notes 2008, 1:135 http://www.biomedcentral.com/1756-0500/1/135
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We calculated the yield of recombination (0.02%) by
counting the kanamycin-resistant colonies of the pir-
strain transformed by the recombination mix and taking
into account the transformation efficiency (2.2 × 10^8
colonies/mkg DNA) (Fig. 3, and data not shown).
In order to test the integrity of the recombination product,
we have picked either kanamycin- or chloramphenicol-
resistant colonies, isolated plasmid DNA and digested it
with an appropriate restriction enzyme. We used EcoRI in
case of recombination between pINS-Puro and phrGFP.
All colonies gave the restriction pattern expected for the
product of recombination, thus efficiency of the resistance
marker introduction is close to 100% (Fig 4 and data not
shown). Moreover, due to the directional nature of the
LoxP sites, integration occurs in only one orientation
depending on the orientation of the LoxP sites. This fea-
ture makes the population of recombinant vectors highly
homogenous (Fig. 4 and data not shown).
Next we have verified whether the function of Puro-, Blast-
or G418-resistance genes from the pINS-plasmids and the
gene of interest from the target vector is preserved in the
product of recombination. For this purpose we have per-
formed the recombination between each of the three
insertion vectors (pINS-Neo, pINS-Puro and pINS-Blast)
and the target vector phrGFP. Then we have transformed
the recombination mix into the pir- strain and selected the
Upper part. Schematic representation of the Cre-mediated recombination between Insertion vector pINS-Neo and Target  vector phrGFP Figure 3
Upper part. Schematic representation of the Cre-mediated recombination between Insertion vector pINS-
Neo and Target vector phrGFP. Lower part. XL1 Blue (pir+) and BW23474 (pir-) E. coli strains were transformed by the 
pINS-Puro, phrGFP vectors (50 ng each) and the recombination mix (Neo × GFP). 1/10th of the transformed cells was selected 
on the LB plates containing either ampicillin or kanamycin. Insertion vector pINS-Neo containing R6Kγ can transform pir+ but 
not pir- strain and produces kanamycin-resistant colonies. Target vector phrGFP containing pUC-origin can transform pir+ as 
well as pir- strain and produces ampicillin-resistant colonies. Recombination mix contains initial vectors as well as the product 
of recombination and thus can transform both pir- and pir+ strains and produce ampicillin and kanamycin-resistant colonies. 
Only the recombination product containing both pUC-origin and Kan-marker can produce kanamycin-resistant colonies of the 
pir- strain.
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cells containing the product of recombination by growing
them on the kanamycin- or chloramphenicol-containing
plates. Then we transfected the initial plasmids and the
product of recombination (Neo × GFP, Puro × GFP and
Blast × GFP) into HeLa cells and analyzed their resistance
to either puromycin, blasticidin S or G418. As expected,
only pINS vectors and the products of recombination pro-
vided the HeLa cells with the resistance against blasticidin
S, puromycin and G418 (Fig 5).
Then HeLa cells resistant to the antibiotics were inspected
under the microscope for the expression of GFP. Only
cells transfected by the recombination products were GFP-
positive. Moreover, the proportion of the GFP-positive
cells was considerably higher than in the case of transient
transfection by the phrGFP plasmid (Fig 6). We conclude
that our recombination procedure can "safely" merge the
antibiotic resistance gene and the gene of interest in one
plasmid.
Discussion
Researchers working with the vectors suitable for expres-
sion in mammalian cells often meet with the puzzle of
how to quickly introduce or switch the antibiotic resist-
ance gene in the vector of interest. In this paper we
describe the pINS vectors suitable for introduction of anti-
biotic resistance genes in any plasmid of interest contain-
ing the LoxP site by Cre-mediated recombination. We
cloned the genes providing resistance to three frequently
used antibiotics (puromycin, blasticidin S and G418) in
the pUNI-10 plasmid [12]. The plasmid pUNI-10 con-
tains the R6Kγ origin of replication which is inactive in
majority of E. coli strains routinely used for cloning (they
are  pir-). The plasmid resulting from recombination
between the pINS and a target vectors acquires a gene of
interest (provided by the target vector) and resistance to
an antibiotic (puromycin, blasticidin S or G418) (pro-
vided by pINS vector). The principle of selection in based
on the acquisition of the functional origin of replication
pINS plasmids are introduced always in the same orientation Figure 4
pINS plasmids are introduced always in the same orientation. Upper part. Schematic representation of the Cre-
mediated recombination between Insertion vector pINS-Puro and Target vector phrGFP. Recombination intermediate and the 
sizes of the plasmids are shown. Lower part. Orientation of the pINS-Puro insert in the product of recombination (Puro × 
GFP) was analyzed by EcoRI. The sizes of the digestion products were analyzed on the agarose gel. We observed the fragments 
specific to only one orientation of the pINS-Puro in the product of recombination. This orientation is determined by the orien-
tation of loxP sites.
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(provided by the target vector) as well as the marker pro-
viding resistance to kanamycin or chloramphenicol (pro-
vided by the pINS vector). Combination of these features
makes it possible to select the recombinant plasmids by
transforming the recombination mix into a pir- E. coli
strain and selecting the kanamycin- or chloramphenicol-
positive colonies (Fig. 1). These two features are necessary
and sufficient for selection of the recombinant plasmids.
Utilization of two antibiotics (chloraphenicol/kanamy-
cin+ampicillin) does not provide any further enhance-
ment to the procedure.
Our method is similar to the procedure used in the exist-
ing pExchanger system (Stratagene). pExchanger system
relies on integration of the linear fragments coding for the
antibiotic resistance genes and selection marker (Kan or
Cam) into the target vector using Cre-recombination. Lin-
ear fragments can't replicate by themselves and thus can't
efficiently transform E. coli. Presumably only the colonies
containing the recombinant plasmids can be selected by
the markers encoded in the linear fragments. In contrast
to pExchanger system, we propose to use the replication-
deficient circular pINS plasmids that can be easily pro-
duced in the user laboratory and thus allow the user to cut
the cost of the cloning.
The Insertion vectors pINS-Puro, pINS-Neo and pINS-
Blast are compatible with the numerous target vectors
already present on the market (for example, pExchange
core or phrGFP vector families, Stratagene). In addition,
virtually any vector of interest can be converted into a tar-
get vector by simple introduction of the LoxP site.
Methods
pINS plasmids
In order to obtain the pINS-Blast vector, the pcDNA6/TR
vector (Invitrogen, Carlsbad, CA, USA) was digested by
XmnI and SalI and the fragment containing blasticidin S
resistance gene was ligated with the pUNI-10 vector
(kindly provided by Dr. Stephen Elledge) digested by
EcoRV and SalI (these and other restriction enzymes were
purchased from Fermentas, Vilnius, Lithuania) using T4
ligase (Fermentas). The product of ligation was trans-
formed by electroporation into the strain BW23474 (Δlac-
Functionality of Blast, Puro and G418-resistance genes from pINS plasmids is preserved in the products of recombination Figure 5
Functionality of Blast, Puro and G418-resistance genes from pINS plasmids is preserved in the products of 
recombination. Left part. Colony forming assay. HeLa cells transfected by 1 mkg of indicated plasmids were selected by 
either blasticidin S, puromycin or G418. After completion of selection the cells were stained by methylene blue. Insertion vec-
tors pINS-Blast, pINS-Neo and pINS-Puro and the products of their recombination with Target vector phrGFP (Blast × GFP, 
Neo × GFP and Puro × GFP) provide HeLa cells with the resistance to blasticidin S, G418 or puromycin respectively. Right 
part. Schematic representation of the Cre-mediated recombination between Insertion vectors pINS-Blast, pINS-Neo and 
pINS-Puro and Target vector phrGFP.
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169 rpoS(Am) robA1 creC510 hsdR514 endA recA1 uidA
(ΔMluI)::pir-116) that was kindly provided by Dr.
Stephen Elledge, and selected using kanamycin. The
resulting plasmid was named pINS-Blast.
In order to obtain the pINS-Puro vector, the pPur plasmid
(Clontech, Terra Bella, CA, USA) was digested by NdeI,
blunt-ended using Klenow fragment (Fermentas), then
digested by BamHI and ligated with the fragment of
pACYC-184 plasmid [27] containing Cam resistance gene
(pACYC-184 was purchased from Fermentas). In order to
obtain this fragment we first digested pACYC-184 by BclI,
treated it with Klenow fragment, then digested with
BamHI. The product of ligation was named pACYC-Puro.
pACYC-Puro was digested by Bst1107I, BamHI, then
blunt-ended with Klenow fragment. The fragment con-
taining chloramphenicol and puromycin resistance genes
was ligated with pUNI-10 vector digested EcoRI and BglII
and blunt-ended with Klenow fragment. The product of
ligation was transformed via electroporation in BW23474
strain and selected via chloramphenicol. The resulting
plasmid was named pINS-Puro.
In order to obtain the pINS-Neo vector, pCINeo plasmid
(Promega, Madison, WI, USA) was digested by BamHI
and the fragment containing pUC-origin, ampicillin and
neomycin resistance genes was ligated to BamHI-linear-
ized pUNI-10 resulting in the plasmid "3490". Plasmid
"3490" was digested by XbaI and self-ligated in order to
remove ampicillin resistance gene and pUC-origin of rep-
Functionality of GFP gene from phRGFP plasmid is preserved in the products of recombination with pINS-Puro, pINS-Neo or  pINS-Blast plasmids Figure 6
Functionality of GFP gene from phRGFP plasmid is preserved in the products of recombination with pINS-
Puro, pINS-Neo or pINS-Blast plasmids. HeLa cells transfected by 1 mkg of either Target vector phrGFP or the products 
of recombination (Blast × GFP, Neo × GFP and Puro × GFP). Cells transfected by the recombination products were selected 
by either blasticidin S, G418 or puromycin and stained by DAPI. Expression of the GFP was analyzed under the microscope. In 
case of transient transfection by phrGFP vector we usually observed 25% GFP positive cells. In contrast we observed that 80–
100% of the cells transfected by the products of recombination and selected by the corresponding antibiotics are GFP positive. 
Scale bar: 20 μm.
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lication. The product of ligation was transformed into the
BW23474 strain via electroporation and selected using
kanamycin. The resulting plasmid was named pINS-Neo.
Target vectors
In order to prepare the pT-FLAG vector, we digested
phrGFP vector (Stratagene) by NheI and EcoRI and
replaced the GFP ORF by the oligonucleotide duplex
encoding the FLAG-tag (oligo1: 5'-CTAGCCCATGGATTA-
CAAAGACGATGACGATAAACCTAGCTTCG; oligo2: 5'-
AATTCGAAGCTAGGTTTATCGTCATCGTCTTTGTAATC-
CATGGG) (Sigma, St. Louis, MO, USA). Then LoxP-site
coupled to ampicillin resistance gene was isolated from
pT-FLAG plasmid by BspHI digestion and cloned into
phRL-TK (Promega, Madison, WI, USA) or pBlueScriptII
(Stratagene) digested by BspHI. The resulting plasmids
were named pT-TK and pT-BS respectively.
In vitro Cre recombination
500 ng of pINS vector was mixed with 500 ng of target vec-
tor, 5 units of Cre recombinase (Stratagene, La Jolla, CA,
USA), and a buffer recommended by manufacturer in 10
mkl reaction volume. The reaction was incubated for 30
min at 37°C, then Cre recombinase was heat-inactivated
at 65°C for 20 min. The recombination mix was trans-
formed by electroporation into XL1-Blue E. coli strain
(recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F'
proAB lacIqZΔM15 Tn10 (Tetr)]) purchased from Strata-
gene and selected using either 34 mkg/ml chlorampheni-
col (Euromedex) or 50 mkg/ml kanamycin (Euromedex,
Mundolsheim, France).
Testing the performance of the constructs in HeLa
Dulbecco's modified Eagle's medium (DMEM #31885
Gibco, Carlsbad, CA, USA) supplemented with 10% heat-
inactivated Millerium Fetal Bovine Serum (#BWSTS1810
VWR International, Fontenay-sous-Bois, France), 100
units/ml penicillin G and 100 mkg/ml streptomycin sul-
fate (Gibco) and 500 ng/ml Fungizone (Invitrogen) in the
presence of 5% CO2. Cells were transfected by 1 mkg of
plasmid DNA using JetPEI (Polyplus-transfection Inc.,
New York, NY, USA) according to the protocol provided
by supplier. 24 hours after transfection media was
replaced and the cells were either grown for another 24
hours (transient transfection) or selected with either 3
mg/ml puromycin (Sigma #P8833) for 3 days, 5 mg/ml
blasticidin S (Sigma #15205) for 5 days or 1 mg/ml G418
(Sigma #G8168) for 10 days until the complete death of
mock-transfected cells. Transfected cells were either
stained by 1% methylene blue (Euromedex #A514) in
50% methanol or mounted on the slides, stained by 100
ng/ml DAPI (Sigma #D9542) and inspected under the flu-
orescent microscope Olympus AX70.
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